Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones

Abstract

The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

1 - 11 . (canceled) 
     
     
         12 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) in free form or in pharmaceutically acceptable salt form which is 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  is a five- to six-membered monocyclic saturated or unsaturated non-aromatic ring system, wherein said ring system may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, and wherein said ring system may be substituted once or more than once by R 6 ; 
 
       and
 R 2  is C 2-6 alkyl which may be substituted once or more than once by R 7 ; 
 
       or R 2  is —X 1 —R 8 ; —X 1 — is —O—, —S— or —N(R 9 )—; R 9  is hydrogen or C 1-4 alkyl; and R 8  is C 1-6 alkyl which may be substituted once or more than once by R 10 ; 
       or R 2  is a three- to five-membered monocyclic saturated or unsaturated non-aromatic ring system, wherein said ring system may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, and wherein said ring system may be substituted once or more than once by R 11 ; 
       or
 R 1  is 
 
       
         
           
           
               
               
           
         
       
       wherein the phenyl ring is attached via the bond marked with an asterisk; 
       each R 12  independently is hydrogen, halogen, hydroxyl, amino, cyano, nitro, C 1-4 alkyl, C 1-4 halogenalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy-C 1-4 alkyl, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, di(C 1-4 alkyl)-amino-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halogenalkoxy, C 1-4 alkylamino or di(C 1-4  alkyl)amino; or C 3-6 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-6 cycloalkyl may be attached directly or via a C 1-2 alkylene, and wherein the C 3-6 cycloalkyl may be substituted once or more than once by halogen; 
       and
 R 2  is C 2-7 alkyl which may be substituted once or more than once by R 13 ; 
 
       or R 2  is —X 2 —R 14 ; —X 2 — is —O—, —S— or —N(R 15 )—; R 15  is hydrogen or C 1-4 alkyl; and R 14  is C 1-6 alkyl which may be substituted once or more than once by R 16 ; 
       or R 2  is a three- to five-membered monocyclic saturated or unsaturated non-aromatic ring system, wherein said ring system may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, and wherein said ring system may be substituted once or more than once by R 17 ;
 R 3  is hydrogen or —CH 2 R 18 ; 
 R 18  is hydrogen, C 1-4 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, C 1-3 alkoxyC 1-3 alkyl, hydroxyC 1-3 alkyl, or aminoC 1-3 alkyl; 
 
       and
 R 4  is hydrogen, halogen, hydroxyl, amino, cyano, C 1-4 alkyl, C 1-4 halogenalkyl, C 1-4  hydroxyalkyl, C 1-4 alkoxy-C 1-4 alkyl, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, di(C 1-4 alkyl)-amino-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halogenalkoxy, C 1-4 alkylamino or di(C 1-4 alkyl)amino; 
 
       or a three- to seven-membered monocyclic aromatic, saturated or unsaturated non-aromatic ring system, wherein said ring system may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein said ring system may be attached directly or via a C 1-2  alkylene, and wherein said ring system may be substituted once or more than once by R 19 ; 
       or
 R 3  and R 4  taken together are —CH 2 —CH 2 —; 
 R 5  is hydrogen, halogen, hydroxyl, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkinyl or C 1-4 alkoxy; or C 3-4 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-4 cycloalkyl may be attached directly or via a C 1-2 alkylene; 
 R 6 , R 11 , R 17  and R 19  each independently is halogen, hydroxyl, amino, cyano, nitro, C 1-4 alkyl, C 1-4 halogenalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy-C 1-4 alkyl, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4  alkyl, di(C 1-4 alkyl)-amino-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halogenalkoxy, C 1-4 alkylamino or di(C 1-4  alkyl)amino; 
 
       or C 3-6 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-6 cycloalkyl may be attached directly or via a C 1-2 alkylene, and wherein the C 3-6 cycloalkyl may be substituted once or more than once by halogen; 
       or two R 6 , R 11 , R 17  or R 19  at the same ring atom together are oxo; 
       or two R 6 , R 11 , R 17  or R 19  at the same ring carbon atom together with said carbon atom form a C 3-6 cycloalkyl;
 R 7 , R 10 , R 13  and R 16  each independently is halogen, hydroxyl, amino, cyano, nitro, C 1-4 alkoxy, C 1-4 halogenalkoxy, C 1-4 alkylamino or di(C 1-4 alkyl)amino; 
 
       or C 3-6 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-6 cycloalkyl may be attached directly or via a C 1-2 alkylene, and wherein the C 3-6 cycloalkyl may be substituted once or more than once by halogen; 
       or two R 7 , R 10 , R 13  or R 16  at the same carbon atom together are oxo; 
       or two R 7 , R 10 , R 13  or R 16  at the same carbon atom together with said carbon atom form a C 3-6 cycloalkyl. 
     
     
         13 . A pharmaceutical composition according to  claim 12  wherein
 R 1  is 
 
       
         
           
           
               
               
           
         
       
       wherein the phenyl ring is attached via the bond marked with an asterisk; 
       each R 12  independently is hydrogen, halogen, hydroxyl, amino, cyano, nitro, C 1-4 alkyl, C 1-4 halogenalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy-C 1-4 alkyl, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, di(C 1-4 alkyl)-amino-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halogenalkoxy, C 1-4 alkylamino or di(C 1-4  alkyl)amino; or C 3-6 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-6 cycloalkyl may be attached directly or via a C 1-2 alkylene, and wherein the C 3-6 cycloalkyl may be substituted once or more than once by halogen; 
       and
 R 2  is C 2-7 alkyl which may be substituted once or more than once by R 13 ; 
 
       or R 2  is —X 2 —R 14 ; —X 2 — is —O—, —S— or —N(R 15 )—; R 15  is hydrogen or C 1-4 alkyl; and R 14  is C 1-6 alkyl which may be substituted once or more than once by R 16 ; 
       or R 2  is a three- to five-membered monocyclic saturated or unsaturated non-aromatic ring system, wherein said ring system may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, and wherein said ring system may be substituted once or more than once by R 17 ;
 R 3  is hydrogen or —CH 2 R 18 ; 
 R 18  is hydrogen, C 1-4 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, C 1-3 alkoxyC 1-3 alkyl, hydroxyC 1-3 alkyl, or aminoC 1-3 alkyl; 
 
       and
 R 4  is hydrogen, halogen, hydroxyl, amino, cyano, C 1-4 alkyl, C 1-4 halogenalkyl, C 1-4  hydroxyalkyl, C 1-4 alkoxy-C 1-4 alkyl, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, di(C 1-4 alkyl)-amino-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halogenalkoxy, C 1-4 alkylamino or di(C 1-4 alkyl)amino; 
 
       or a three- to seven-membered monocyclic aromatic, saturated or unsaturated non-aromatic ring system, wherein said ring system may contain from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein said ring system may be attached directly or via a C 1-2  alkylene, and wherein said ring system may be substituted once or more than once by R 19 ; 
       or
 R 3  and R 4  taken together are —CH 2 —CH 2 —; 
 R 5  is hydrogen, halogen, hydroxyl, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkinyl or C 1-4 alkoxy; or C 3-4 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-4 cycloalkyl may be attached directly or via a C 1-2 alkylene; 
 R 13  and R 16  each independently is halogen, hydroxyl, amino, cyano, nitro, C 1-4 alkoxy, C 1-4  halogenalkoxy, C 1-4 alkylamino or di(C 1-4 alkyl)amino; 
 
       or C 3-6 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-6 cycloalkyl may be attached directly or via a C 1-2 alkylene, and wherein the C 3-6 cycloalkyl may be substituted once or more than once by halogen; 
       or two R 13  or R 16  at the same carbon atom together are oxo; 
       or two R 13  or R 16  at the same carbon atom together with said carbon atom form a C 3-6 cycloalkyl;
 R 17  and R 19  each independently is halogen, hydroxyl, amino, cyano, nitro, C 1-4 alkyl, C 1-4  halogenalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy-C 1-4 alkyl, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4  alkyl, di(C 1-4 alkyl)-amino-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 halogenalkoxy, C 1-4 alkylamino or di(C 1-4  alkyl)amino; 
 
       or C 3-6 cycloalkyl, wherein one carbon atom may be replaced by an oxygen atom, wherein the C 3-6 cycloalkyl may be attached directly or via a C 1-2 alkylene, and wherein the C 3-6 cycloalkyl may be substituted once or more than once by halogen; 
       or two R 17  or R 19  at the same ring atom together are oxo; 
       or two R 17  or R 19  at the same ring carbon atom together with said carbon atom form a C 3-6 cycloalkyl. 
     
     
         14 . A pharmaceutical composition according to  claim 12  wherein the compound is selected from
 2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 10-methyl-2-pentyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 10-methyl-3-phenyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 2-ethyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-(3,5-dimethylphenyl)-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-(3,5-dimethylphenyl)-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-(3,5-dimethylphenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-(3,5-dimethylphenyl)-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-cyclopentyl-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-cyclopentyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-cyclohexyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; 
 3-cyclohexyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; or 
 3-cyclopentyl-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione. 
 
     
     
         15 . A compound which is selected from the group consisting of
 2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   10-allyl-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   10-allyl-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   10-methyl-2-(3-methylcyclobutyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(3,3-dimethylcyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(3-methoxycyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   10-methyl-2-(pentan-3-yl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-cyclopentyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-cyclopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-butyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(3-methoxypropyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(4-methoxybutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-(2-fluorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-(2-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-(2,6-dichlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-10-methyl-3-(o-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-3-(2-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-10-methyl-3-(2-(trifluoromethyl)phenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-(3-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10 OH)-dione;   2-isopropyl-3-(3-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   7-fluoro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   7-chloro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   7-bromo-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-7,10-dimethyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   9-isopropyl-8-phenyl-1H-pyrimido[4,5-b]pyrrolo[3,2,1-ij]quinoline-6,7(2H,8H)-dione;   10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-cyclopentyl-10-ethyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(sec-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-cyclopentyl-2-isobutyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(tert-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-10-methyl-3-(piperidin-1-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-cyclopentyl-2-isopropyl-9-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-cyclopentyl-2-isopropyl-7-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   7-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   7-bromo-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-cyclopentyl-7-ethynyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-cyclopentyl-2-isopropyl-10-methyl-4,5-dioxo-3,4,5, 10-tetrahydropyrimido[4,5-b]quinoline-7-carbonitrile;   9-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-(dimethylamino)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione; and   2-(dimethylamino)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   10-(2-aminoethyl)-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-3-(2-isopropylphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-cyclobutyl-10-(2-hydroxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   3-(2-bromophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   10-(2-aminoethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   10-(2-hydroxyethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-10-(2-methoxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-3-phenyl-10-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-3-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-cyclobutyl-3-(2,6-dichlorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-hexyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   2-heptyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;   
       or salts of these compounds. 
     
     
         16 . A combination comprising a therapeutically effective amount of the compound of formula (I) as described in  claim 15  in free form or in pharmaceutically acceptable salt form and one or more therapeutically active agents.